Table 1.
Clinical characteristics of the entire cohort of patients (n = 47)
| n | % | |
|---|---|---|
| Median age, y (range) | 55 (24-73) | |
| Sex (female/male) | 26/21 | 55/45 |
| Diagnosis (WHO 2022/ICC 2022) | ||
| AML myelodysplasia–related | 24/29 | 49/61 |
| Previous MDS | 5/5 | 11/11 |
| MDS-defining cytogenetics | 4/4 | 8/8 |
| MDS-defining mutations | 19/26 | 40/55 |
| AML-DD | 22/17 | 47/37 |
| With minimal differentiation | 3/1 | 6/2 |
| Without maturation | 8/7 | 17/15 |
| With maturation | 2/2 | 4/4 |
| Myelomonocytic | 3/2 | 6/4 |
| Monoblastic/monocytic | 6/5 | 13/11 |
| Myeloid sarcoma | 1/1 | 2/2 |
| Cytogenetics | ||
| MRC-defined intermediate risk | 43 | 96 |
| Normal karyotype | 32 | 71 |
| MRC-defined adverse risk | 2 | 4 |
| ELN 2022 defined genetic risk | ||
| Intermediate risk | 23 | 49 |
| Adverse risk | 24 | 51 |
| Somatically mutated genes | ||
| DNMT3A | 14 | 30 |
| RUNX1 | 13 | 28 |
| FLT3 (ITD/TKD) | 7/5 | 15/11 |
| IDH2 | 9 | 19 |
| IDH1 | 7 | 15 |
| Treatment received | ||
| Intensive induction chemotherapy | 44 | 94 |
| AlloHCT | 35 | 80 |
| Autologous HCT | 2 | 4 |
| Disease response after induction (n = 44) | ||
| Complete response | 37 | 88 |
| Refractory disease | 5 | 12 |
ELN 2022, European LeukemiaNet; ICC 2022, International Consensus Classification; ITD, internal tandem duplication; MRC, Medical Research Council cytogenetic category; TKD, tyrosine kinase domain; WHO 2022, World Health Organization classification.